And then, later on, when we do — if assuming we do getting FDA clearance, we would then, at that point, be able to have an announcement to that effect at a later date. So that’s our current strategy. At this juncture, if things go according to plan, we do think that the timing of an FDA clearance may work out very well with where we are with setting up all the manufacturing we mentioned earlier in the call, getting that established and ready to go for the launch. So that’s that process. And then, any against the second part of that question, maybe any risks associated with the product coming to the market. We’ve had — we have a very talented contract manufacturing firm we’re working with. And they’re a large firm. They’ve done this before.
Our product will be manufactured in a medical device manufacturing facility. And so, we feel pretty confident that we are developing the right processes to be able to manufacture the product in large quantities. We also have done a really great job in terms of sourcing the raw materials that we need. We have an incredibly seasoned VP of Operations who from day 1 was really focused on supply chain recognizing that ship to get in, challenges that persisted through the course of COVID. And we feel like we’re in a really good place as it relates to all of the components. And so, as we continue to execute the way we have before and we’ve got a very seasoned team, I don’t see at this moment anything that’s going to cause us to have a problem as it relates to our ability to execute and get this product out in the summer.
J. Cogan: Great. Thanks, John. We’ve got a couple more and I can probably take those at least from the webcast and then maybe operator we’ll see if there’s any more on the phones. One question is, what unit production capacity are we planning for the initial summer launch of the ring? As we have mentioned on numerous occasions, we’re not going to provide financial guidance, but I think as you heard in John’s comments just now and also how we were kind of characterizing this on the — in the script for today, we’re going to be well prepared in terms of parts and capabilities to deliver thousands and thousands of units initially. And we have plans for how we think that this is going to play out from an overall demand standpoint.
So, we’re getting positioned for that. We feel good about it. And we’re looking forward to the launch obviously. And then another question about when we might be able to announce the partner’s names for both studies, or I guess betas this questioner is referring to? We’ve announced the partners that we can thus far. Obviously, we’d like to be able to announce more partners as we move through time. And certainly, as soon as we’re able to, we will keep you posted. As we have mentioned, we’ve been working with Stanford and their athletic department. We’re working with Novant Health, who is an integrated health network down in the Southeast in the Carolinas and Georgia. They have 6 million annual patient visits a year. They generate $7 billion in revenue.
And then, we’re working with three global medical device companies, one major pharmaceutical company, one global athletic apparel retailer, which we announced today as well. And so that pretty much fills out the others that we are working with. And then, finally, at least in terms of the webcast questions, there’s a question about future capital raising and all that. The question says, first COVID, then supply shocks, inflation and now banks in crisis mode, how does this affect your efforts to raise capital as you look out over the next six to 12 months? Well, obviously, we’ve been navigating some choppy macro waters. And as noted earlier in the call, we have no material exposure to Silicon Valley Bank or the regional banks in general. We’re working with multiple multinational banks to help mitigate these types of systemic risks as we mentioned earlier.
